Key facts
- It has raised $9.8M; the latest was Seed Round in Mar 2026.
- Notable investors include International Finance (Washington D.C.), Sofinnova Partners, OTB Ventures, Inovo VC.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Ingenix.ai
- ·The full record, as it builds
Funding rounds
No funding rounds for Ingenix.ai are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ingenix.ai
Developer of a multimodal generative AI platform designed to simulate clinical trials and predict outcomes across biological systems. The company offers a co-pilot platform integrating multimodal biomedical data and multiscale modeling capabilities, enabling pharmaceutical and clinical research teams to improve drug development decisions and reduce trial uncertainty.
- Sector
- Healthcare
- HQ
- Warsaw, Poland
- Founded
- 2023
- Employees
- 32
- Website
- ingenix.ai/
- Ownership
- Privately Held (backing)
Ingenix.ai doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ingenix.ai shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ingenix.ai in its N-PORT filings yet. We sweep new filings monthly.